We are live on ! Find out more
MGX icon

Metagenomi Therapeutics
MGX

69 hedge funds and large institutions have $10.4M invested in Metagenomi Therapeutics in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 20 increasing their positions, 20 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 20

5.57% less ownership

Funds ownership: 26.18% → 20.61% (-5.6%)

13% less funds holding

Funds holding: 79 → 69 (-10)

23% less capital invested

Capital invested by funds: $13.5M → $10.4M (-$3.15M)

38% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 26

Holders
69
Holders Change
-10
Holders Change %
-12.66%
% of All Funds
0.91%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
16
Increased
20
Reduced
20
Closed
26
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PVI
Pura Vida Investments
New York
+$1.08M
2
Millennium Management
Millennium Management
New York
+$310K
3
Jane Street
Jane Street
New York
+$249K
4
PLC
Peapod Lane Capital
New York
+$244K
5
Marshall Wace
Marshall Wace
United Kingdom
+$235K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$1.95M
2
PHS
PFM Health Sciences
California
-$1.2M
3
State Street
State Street
Massachusetts
-$683K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$511K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$312K
Name Holding Trade Value Shares
Change 		Change in
Stake
SEI Investments
76
SEI Investments
Pennsylvania
– -$37.7K -27,751 Closed
PCM
77
Prelude Capital Management
New York
– -$34.8K -25,556 Closed
PWPS
78
Pinnacle Wealth Planning Services
Ohio
– -$33.4K -24,583 Closed
IIM
79
INTECH Investment Management
Florida
– -$31.6K -23,200 Closed
Mirae Asset Global ETFs Holdings
80
Mirae Asset Global ETFs Holdings
Hong Kong
– -$21.6K -15,895 Closed
RhumbLine Advisers
81
RhumbLine Advisers
Massachusetts
– -$20.9K -15,399 Closed
QC
82
Quadrature Capital
United Kingdom
– -$19.5K -14,198 Closed
New York State Common Retirement Fund
83
New York State Common Retirement Fund
New York
– -$18.9K -13,900 Closed
Pathstone Holdings
84
Pathstone Holdings
New Jersey
– -$18.6K -13,648 Closed
Bank of Montreal
85
Bank of Montreal
Ontario, Canada
– -$18.3K -13,441 Closed
CF
86
Corebridge Financial
Texas
– -$18.2K -13,403 Closed
TFS
87
Thoroughbred Financial Services
Tennessee
– -$17K -12,500 Closed
Mariner
88
Mariner
Kansas
– -$14.9K -10,939 Closed
T. Rowe Price Associates
89
T. Rowe Price Associates
Maryland
– -$15K -10,755 Closed
Legal & General Group
90
Legal & General Group
United Kingdom
– -$3.69K -2,701 Closed
California State Teachers Retirement System (CalSTRS)
91
California State Teachers Retirement System (CalSTRS)
California
– -$2.8K -2,060 Closed
AB
92
Amalgamated Bank
New York
– -$1K -944 Closed
Royal Bank of Canada
93
Royal Bank of Canada
Ontario, Canada
– -$1K -647 Closed
AIP
94
Ameritas Investment Partners
Nebraska
– -$840 -618 Closed
SCM
95
Sterling Capital Management
North Carolina
– -$258 -190 Closed
1 2 3
4

MGX Hedge Fund Activity: Q2 2025 in Review

69 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q2 2025, worth a combined $10.4M — down 23% from $13.5M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of MGX and 16 opened new positions — a net loss of 10 holders — while 20 trimmed existing stakes and 20 added.

The largest buyer was Pura Vida Investments, adding an estimated $1.08M. The largest seller was BlackRock, cutting an estimated $1.95M.

  • 69 institutional investors held Metagenomi Therapeutics (MGX) as of Q2 2025, down from 79 in Q1 2025.
  • Funds reported $10.4M of Metagenomi Therapeutics stock for Q2 2025, down 23% quarter-over-quarter.
  • 16 funds opened new Metagenomi Therapeutics positions in Q2 2025 and 26 closed out, a net change of -10 holders.
  • The largest Metagenomi Therapeutics buyer in Q2 2025 was Pura Vida Investments, an estimated $1.08M added.
  • The largest Metagenomi Therapeutics seller in Q2 2025 was BlackRock, an estimated $1.95M sold.

Based on aggregated 13F filings for Q2 2025.